Sangamo Therapeutics (SGMO) Competitors $0.74 -0.01 (-1.80%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMO vs. ZBIO, RIGL, VSTM, VNDA, EBS, XOMA, IRWD, CDXS, LXRX, and RGLSShould you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Lexicon Pharmaceuticals (LXRX), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Sangamo Therapeutics vs. Zenas Biopharma Rigel Pharmaceuticals Verastem Vanda Pharmaceuticals Emergent BioSolutions XOMA Ironwood Pharmaceuticals Codexis Lexicon Pharmaceuticals Regulus Therapeutics Sangamo Therapeutics (NASDAQ:SGMO) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Does the media prefer SGMO or ZBIO? In the previous week, Sangamo Therapeutics had 1 more articles in the media than Zenas Biopharma. MarketBeat recorded 14 mentions for Sangamo Therapeutics and 13 mentions for Zenas Biopharma. Sangamo Therapeutics' average media sentiment score of 0.35 beat Zenas Biopharma's score of 0.01 indicating that Sangamo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, SGMO or ZBIO? Zenas Biopharma has lower revenue, but higher earnings than Sangamo Therapeutics. Zenas Biopharma is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSangamo Therapeutics$57.80M2.92-$257.83M-$0.52-1.44Zenas Biopharma$5M71.06-$148.39M-$3.55-2.39 Do institutionals and insiders believe in SGMO or ZBIO? 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer SGMO or ZBIO? Sangamo Therapeutics received 454 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 62.72% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformSangamo TherapeuticsOutperform Votes45662.72% Underperform Votes27137.28% Zenas BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Do analysts prefer SGMO or ZBIO? Sangamo Therapeutics currently has a consensus target price of $5.17, suggesting a potential upside of 588.43%. Zenas Biopharma has a consensus target price of $40.00, suggesting a potential upside of 370.59%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Zenas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SGMO or ZBIO more profitable? Zenas Biopharma has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. Zenas Biopharma's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics-257.87% -264.16% -107.24% Zenas Biopharma N/A N/A N/A SummarySangamo Therapeutics beats Zenas Biopharma on 10 of the 17 factors compared between the two stocks. Remove Ads Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMO vs. The Competition Export to ExcelMetricSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.65M$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-1.0030.3721.7417.78Price / Sales2.92438.19376.0494.51Price / Cash30.42168.6838.1534.64Price / Book1.603.456.443.99Net Income-$257.83M-$72.06M$3.20B$247.24M7 Day Performance19.54%8.22%6.19%6.12%1 Month Performance-23.51%-17.76%-8.79%-7.11%1 Year Performance35.20%-29.82%9.69%-0.85% Sangamo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMOSangamo Therapeutics2.1794 of 5 stars$0.74-1.8%$5.17+601.0%+38.1%$166.06M$57.80M-0.99480Gap UpZBIOZenas BiopharmaN/A$7.89+2.3%$40.00+407.0%N/A$329.79M$5M-2.22N/AGap DownRIGLRigel Pharmaceuticals2.6035 of 5 stars$16.91-1.9%$36.80+117.6%+43.4%$301.71M$179.28M120.65160News CoveragePositive NewsGap UpVSTMVerastem2.9138 of 5 stars$4.98-3.5%$13.88+178.6%-57.7%$256.41M$10M-1.5650Gap UpVNDAVanda Pharmaceuticals4.0853 of 5 stars$4.19+1.1%$16.50+294.3%+5.8%$242.54M$198.77M-13.00290News CoverageGap DownEBSEmergent BioSolutions3.8368 of 5 stars$4.43-2.0%$14.33+223.6%+123.8%$241.53M$1.01B-1.082,420XOMAXOMA4.4429 of 5 stars$19.21-1.2%$72.00+274.7%-21.5%$230.18M$10.22M-5.5210News CoverageIRWDIronwood Pharmaceuticals4.3282 of 5 stars$1.23-8.6%$8.60+602.0%-91.8%$194.43M$351.41M-40.50220Analyst DowngradeShort Interest ↓News CoverageGap DownCDXSCodexis3.107 of 5 stars$2.05-4.0%$8.33+307.5%-19.9%$169.40M$59.35M-2.35250Gap UpLXRXLexicon Pharmaceuticals2.783 of 5 stars$0.51+21.0%$3.67+623.2%-73.1%$124.84M$31.08M-0.68140Analyst ForecastHigh Trading VolumeRGLSRegulus Therapeutics2.3931 of 5 stars$1.66-1.5%$12.75+668.1%-31.8%$109.63MN/A-1.5530Short Interest ↑ Remove Ads Related Companies and Tools Related Companies ZBIO Alternatives RIGL Alternatives VSTM Alternatives VNDA Alternatives EBS Alternatives XOMA Alternatives IRWD Alternatives CDXS Alternatives LXRX Alternatives RGLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMO) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
